Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Khanh T DoBose KochupurakkalSarah KellandAdrienne de JongeJennifer HedglinAllison PowersNicholas QuinnCourtney GannonLoan VuongKalindi ParmarJean-Bernard LazaroAlan D' AndreaGeoffrey I ShapiroPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Prexasertib combined with olaparib has preliminary clinical activity in BRCA-mutant patients with HGSOC who have previously progressed on a PARP inhibitor. PD analyses show that prexasertib compromises HR with evidence of induction of DNA damage and replication stress.